Incyte’s PD-(L)1 inhibitor headed for an ODAC showdown next month

Incyte’s PD-(L)1 inhibitor headed for an ODAC showdown next month

Source: 
Endpoints
snippet: 

The FDA’s Oncologic Drugs Advisory Committee will spend a half day on June 24 reviewing Incyte’s PD-(L)1 inhibitor retifanlimab as a treatment for locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) for those who have progressed on or who are intolerant of platinum-based chemotherapy.